Previous 10 | Next 10 |
New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's (NASDAQ: ABMD) Impella heart pumps during high-risk PCI (Protected PCI) enables skilled interventional cardiologists to achieve more complete revascularization, improved ejection fraction ...
Abiomed: Niche and Necessary Products with A Growing Market The world is getting older and sicker. The risk of heart disease has increased across the globe, with an OECD average heart disease mortality rate of 299 per 100,000 people . 39.6% of all American adults and 18.5% of all children...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, May 2, 2019, the Company will release financial results for the fourth quarter of fiscal 2019. The Company will host a conference call to discuss the results on Thursday, May 2, 2019, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, P...
Three years ago this week, Abiomed's (NASDAQ: ABMD) Impella heart pump received its FDA PMA approval for AMI cardiogenic shock . At the time of Impella’s FDA PMA approval, the cardiogenic shock survival rate to explant in the Impella Quality Assurance (IQ) Database was 51% in the...
Prologue Since we mentioned it for the first time four months ago , the US yield curve has inverted further, raising fresh concerns about the risk of an upcoming recession . There are arguments to be made that "this time is different” in interpreting inversion. However, there is...
Abiomed (NASDAQ: ABMD ) plunged another 8.7% on heavy volume in today's trade to cap a 16% swoon over the past four sessions to its lowest price since December, sending the stock below both its 50- and 100-day moving averages. More news on: ABIOMED, Inc., Healthcare stocks news, Stocks on ...
Abiomed Inc. ( ABMD ) is a leading provider of temporary mechanical circulatory support devices. The company focuses on developing, manufacturing and marketing proprietary products that are designed to enable the heart to rest, heal and recover. Besides the established business model and good ...
Data demonstrates survival benefit with the Impella RP Recover Right protocol Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump , announces that survival data from the 18 month post-approval study of 42 I...
The hemodynamic support of Abiomed’s (NASDAQ: ABMD) Impella heart pump platform for high-risk PCI and treatment of cardiogenic shock will be highlighted in more than 30 presentations and posters at the American College of Cardiology’s (ACC) 68th Annual Scientific Session ...
Here is another quality price-gain healthcare stock Making heart pumps since 1981, Abiomed Inc. ( ABMD ) has helped heart failure victims in North America, Europe, and Japan recover life regularly. See what their stock may do for your portfolio’s palpitations at this opportune point...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...